Vedolizumab Entyvio®
The SHIKARI® Vedolizumab portfolio provides two quantitative free-drug formats, qualitative and quantitative ADA assays, and a qualitative target-capture neutralising-antibody assay.
Why Vedolizumab is relevant to biological-drug monitoring research
Vedolizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Vedolizumab is a humanised IgG1 monoclonal antibody that binds α4β7 integrin and reduces gut-selective lymphocyte trafficking by inhibiting interaction with MAdCAM-1. Source ↗
Approved Indications
EMA-authorised uses include moderate-to-severe ulcerative colitis and Crohn’s disease in adults with inadequate response, loss of response or intolerance to specified conventional or advanced therapies. EMA source ↗
IV and SC Trough Exposure
FDA pharmacokinetic data provide formulation- and time-specific trough concentrations:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Five verified Vedolizumab research assays
Ligand-binding ELISA for quantitative analysis of free vedolizumab in human serum or plasma.
Monoclonal anti-idiotypic, mAb-based ELISA for specific quantitative determination of free vedolizumab in human serum or plasma.
Quantitative ELISA for anti-vedolizumab antibodies in human serum or plasma, with assay-specific confirmation.
Qualitative ELISA for positive or negative assessment of anti-vedolizumab antibodies according to assay-specific cut-off interpretation.
Target-capture ELISA for qualitative detection of free neutralising antibodies to vedolizumab in human serum or plasma, using lot-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-VEDO | VED-FD-ENT | Quantitative | Free vedolizumab | Human serum / plasma | 10 µL | 100 min | LOD 1.56 ng/mL; LOQ 3 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® QS-VEDO | VED-SPEC-VED | Quantitative | Free vedolizumab | Human serum / plasma | 10 µL | 100 min | LOD 1 ng/mL; LOQ 3 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATV | VED-QNS-ENT | Quantitative | Anti-vedolizumab antibodies | Human serum / plasma | 20 µL | 140 min | LOD 7.5 ng/mL; LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATV | VED-QLS-ENT | Qualitative | Anti-vedolizumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® T-CAP NAb Assay™ | VED-TCAP-NAb-ENT | Qualitative | Free neutralising anti-vedolizumab antibodies | Human serum / plasma | 10 µL | 140 min | Assay-specific cut-off; positive / negative | 96 | 6 months | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Publications Using SHIKARI® Vedolizumab Kits 1
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Planning a Vedolizumab research study?
Matrix Biotek can help identify the appropriate Vedolizumab assay and prepare regional quotation and delivery information.